Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role

F. Colland (Uitvinder), N. Barker (Uitvinder), J.C. Clevers (Uitvinder), E. Gomez (Uitvinder), M. Lambertus (Uitvinder), E.S. Suils (Uitvinder)

Onderzoeksoutput: Patent (Octrooi)Patent

Samenvatting

The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/.beta.-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/.beta.-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.
Originele taal-2Engels
StatusGepubliceerd - 2006

Vingerafdruk Duik in de onderzoeksthema's van 'Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role'. Samen vormen ze een unieke vingerafdruk.

Citeer dit